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The aim of this study was to characterize the anti-inﬂammatory mode of action of botanical extracts from rosehip (Rosa canina),
willow bark (Salix alba), and nettle leaf (Urtica dioica) in an in vitro model of primary canine articular chondrocytes. Methods. The
biological eﬀects of the botanical extracts were studied in chondrocytes treated with IL-1β for up to 72 h. Expression of collagen
type II, cartilage-speciﬁc proteoglycan (CSPG), β1-integrin, SOX-9, COX-2, and MMP-9 and MMP-13 was examined by western
blotting. Results. The botanical extracts suppressed IL-1β-induced NF-κB activation by inhibition of IκBα phosphorylation,
IκBα degradation, p65 phosphorylation, and p65 nuclear translocation. These events correlated with downregulation of NF-κB
targets including COX-2 and MMPs. The extracts also reversed the IL-1β-induced downregulation of collagen type II, CSPG,
β1-integrin, and cartilage-speciﬁc transcription factor SOX-9 protein expression. In high-density cultures botanical extracts
stimulated new cartilage formation even in the presence of IL-1β. Conclusions. Botanical extracts exerted anti-inﬂammatory and
anabolic eﬀects on chondrocytes. The observed reduction of IL-1β-induced NF-κB activation suggests that further studies are
warranted to demonstrate the eﬀectiveness of plant extracts in the treatment of OA and other conditions in which NF-κB plays
pathophysiological roles.
1. Introduction
Osteoarthritis (OA) is a joint disease involving not only
articular cartilage but also the synovial membrane, sub-
chondral bone and periarticular soft tissues [1]. OA may
occur following traumatic injury to the joint, subsequent
to an infection of the joint or simply as a result of aging.
The symptoms and signs characteristic of OA in the most
frequently aﬀected joints are heat, swelling, pain, stiﬀness
and limited mobility. Other sequelae include osteophyte
formation and joint malalignment. These manifestations
are highly variable, depending on joint location and dis-
ease severity [2]. OA is grossly characterized by aberrant
synthesis of extracellular matrix, gradual hypocellularity,
eventual fragmentation and degradation of cartilage, new
bone formation in the periarticular region (osteophytosis),
decreased, then increased, subchondral bone density, and
variable synovial inﬂammation [3]. In OA, mechanical stress
initiates cartilage lesions by altering chondrocyte-matrix
interaction and metabolic responses in the chondrocytes [4].
The interaction between chondrocytes and matrix pro-
teins is mediated largely by the β1-integrin receptors [5]. This
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interaction plays a crucial role in regulating several biological
phenomena, including cell morphology, gene expression,
and cell survival. β1-integrins are transmembrane signal
transduction receptors mediating cell-matrix interactions in
cartilage [6]. An important signal transduction pathway acti-
vated by β1-integrin receptors is the MAPKinase pathway [7,
8]. Furthermore, disruption of cell matrix communication
by inhibition of the MAPKinase pathway has been shown
to lead to caspase-3 activation, cleavage of Poly(ADP)Ribose
polymerase, and chondrocyte apoptosis [8].
There are initial increases in the amounts of water
and proteoglycans associated with the observed transient
chondrocyte proliferation of early OA. Proliferating chon-
drocytes appear in clusters and are accompanied by a
change in cellular morphology and phenotype, indicating a
hypertrophic diﬀerentiation process. At the molecular level,
OA is characterized by loss of cartilage matrix components,
particularly type II collagen and aggrecan due to an imbal-
ance between extracellular matrix destruction and repair
[9]. Although OA chondrocytes have increased expression
of both anabolic and catabolic matrix genes [10], their
catabolic ability is considered to dominate their anabolic
capacity resulting in cartilage loss. As OA progresses from
mild to severe, there is a decrease in transcription of collagen,
failure to maintain the proteoglycan matrix, and reduced
ability of the chondrocytes to regulate apoptosis [11]. In
contrast, collagen type X, which is normally produced
by terminally diﬀerentiated hypertrophic chondrocytes, has
been demonstrated in surrounding chondrocyte clusters in
OA cartilage [12]. Chondrocyte proliferation (cloning) is
considered to be an attempt to repair and counteract cartilage
degradation. However, disease progression and secondary
inﬂammation indicate that this is generally unsuccessful. The
short-lived hyperplasia (chondrocyte cloning) is followed
by hypocellularity and apoptosis [13]. Catabolic events
responsible for cartilage matrix degradation include (i) the
release of catabolic cytokines such as IL-1β, IL-6, and TNF-α
[14]; (ii) the production of matrix degrading enzymes such
as matrix metalloproteinases (MMPs), mainly, stromelysin-1
(MMP-3) and collagenase-3 (MMP-13); (iii) reactive oxygen
species (ROS) production by chondrocytes in OA [4, 14].
Imbalance between MMPs and tissue inhibitors of MMPs
(TIMPs) occurs, resulting in active MMPs and consequent
cartilage matrix degradation. However, IL-1β may also
contribute to the depletion of cartilage matrix by decreasing
synthesis of cartilage speciﬁc proteoglycans and collagen type
II [4, 15].
The proinﬂammatory eﬀects of IL-1β and TNF-α in OA
are regulated by the transcription factor “nuclear transcrip-
tion factor κB” (NF-κB) [16]. The subunits of NF-κB (p65
and p50) are located in the cytoplasm as an inactive complex
in association with an inhibiting IκBα subunit. In response
to phosphorylation, IκBα dissociates from the complex and
NF-κB translocates to the cell nucleus and binds to target
genes of NF-κB [17]. NF-κB might be also responsible for
downregulation of the transcription factor SOX-9, which
is involved in the regulation of genes for cartilage-speciﬁc
extracellular matrix (ECM) proteins [18].
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) are
currently the most widely used anti-inﬂammatory drugs.
However, they exhibit numerous undesired side eﬀects and
are only temporarily eﬀective. Therefore, naturally occurring
botanical extracts capable of inhibiting NF-κB mediated
catabolic activity may prove to be promising therapeutic
agents for the treatment of OA [19]. Plant extracts with anti-
inﬂammatory activity may also help to reduce the frequency
of consumption and dosage of NSAIDs in arthritis patients.
In recent years there has been a proliferation of research
into botanical extracts with potential anti-inﬂammatory
properties [20]. The most important factor that drives
the interest in botanical extracts is the realization that
inﬂammation plays a central role in the development of
many chronic diseases in humans and companion animals.
The use of herbal medicine is increasing among human
arthritis patients in the United States and western Europe
[21]. According to The Arthritis Foundation, almost 45%
of patients in North America apply ointments or rubs for
OA. A variety of topical and oral preparations are currently
available. Many of these are traditional Chinese, Indian,
or Korean herbal medicines, which have been used in
the armamentarium of indigenous practitioners. The best-
studied botanicals investigated to date include rosehip (Rosa
canina) [22], Tripterygium wilfordii Hook F extract [23],
Triptolide [24], Devil’s Claw (Harpagophytum procumbens)
[25], ginger (Zingiber oﬃcinale Rosc.) [26], and Withania
somnifera (ashwagandha) [27]. In addition, conventional
[28] and several systematic reviews [29] have examined
published evidence for the eﬀectiveness of botanical anti-
inﬂammatory drugs. A few of these have speciﬁcally focused
on the treatment of OA and chronic low back pain [30, 31].
The present study was designed to characterize the eﬀects
and mechanism of action of three botanical extracts; rosehip
(Rosa canina), willow bark (Salix alba), and nettle leaf (Urtica
dioica) in primary canine articular chondrocytes. Previous
studies have reported on the anti-inﬂammatory activity of
Urtica dioica [17, 30, 31]. In this study, we show that these
botanical extracts exhibit a strong capacity for the inhibition
of NF-κB and its regulated gene products in chondrocytes
in vitro.
2. Materials and Methods
2.1. Antibodies. Antibodies to collagen type II (AB746),
β1-integrin (MAB1977), and cartilage-speciﬁc proteogly-
can antibody (MAB2015) were purchased from Millipore
(Schwalbach, Germany). Secondary antibodies were pur-
chased from Dianova (Hamburg, Germany). Antibodies
to β-actin (A5316) were from Sigma (Munich, Germany).
Antibodies raised against MMP-9 (MAB911) and MMP-13
were purchased from R&D Systems (Abingdon, UK). Cyclo-
oxygenase-2 (COX-2) (160-112) antibody was obtained from
Cayman Chemical (Ann Arbor, MI, USA). Monoclonal anti-
ERK antibody and polyclonal anti-Shc antibody were pur-
chased from Becton Dickinson (Heidelberg, Germany).
Antibodies to p65 (IMG-512), phospho-IκBα (IMG-156A)
and pan-IκBα (IMG-127), were obtained from Biocarta
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(Hamburg, Germany). Antibodies to NF-κB p65 (Rel A) and
phospho-speciﬁc pS529 (100-401-266) were obtained from
Rockland laboratories (Biomol, Hamburg, Germany). SOX-
9 antibody was purchased from Acris Antibodies GmbH
(Hiddenhausen, Germany). Peptide aldehydes and a speciﬁc
proteosome inhibitor N-Ac-Leu-Leu-norleucinal (ALLN)
were obtained from Boehringer Mannheim (Mannheim,
Germany). The MTT assay was purchased from Sigma
(Munich, Germany).
2.2. Culture Medium and Chemicals. Culture medium
(Ham’s F-12/Dulbecco’s modiﬁed Eagle’s medium (50/50)
containing 10% fetal calf serum (FCS), 25 μg/mL ascorbic
acid, 50 IU/mL streptomycin, 50 IU/mL penicillin, 2.5 μg/mL
amphotericin B, essential amino acids and L-glutamine) was
obtained from Seromed (Munich, Germany). Trypsin/EDTA
(EC 3.4.21.4) was purchased from Sigma (Munich, Ger-
many). Epon was obtained from Plano (Marburg, Germany).
IL-1β was obtained from Strathman Biotech GmbH (Han-
nover, Germany).
2.3. Preparation of the Botanical Extracts. The botanical
extracts from rosehip (Rosa canina), white willow bark
(Salix alba) and nettle leaf (Urtica dioica) were supplied as
powders from Shamanshop, Camden, NY, USA; catalogue
numbers (202055-51 C, 202295-51 C, and 201865-51 C,
resp.). The botanical extracts were prepared using chloro-
form, a commonly used solvent in the laboratory because it
is relatively unreactive, miscible with most organic liquids,
and conveniently volatile. Also, plant material is commonly
extracted with chloroform for pharmaceutical processing.
Chloroform solvent extractions were carried out by Puleva
Biotech, Granada, Spain. Each botanical extract (∼10 g) was
packed in ﬁlter paper and loaded into the main chamber of
a Soxhlet extraction unit. Chloroform (200 mL) was heated
to reﬂux and incubated for 2 h. Following chloroform-
evaporation under vacuum in a rotary evaporator (placed
in a water bath at 60◦C) the soluble botanical extract
was dissolved in dimethyl sulfoxide (DMSO) at a stock
concentration of 10 mg/mL and stored in aliquots at −80◦C.
The ﬁnal concentration of DMSO did not, in any case, exceed
0.1%. Further dilutions were made in cell culture medium to
achieve the ﬁnal working concentrations.
2.4. Chondrocyte Isolation and Culture. Primary canine artic-
ular chondrocytes were isolated from the joints of client-
owned dogs undergoing orthopaedic surgery at the Clinic of
Veterinary Surgery, Ludwig-Maximilian-University Munich,
Germany. Fully informed owner consent was obtained and
the Ethical Review Committees of WALTHAM, Ludwig-
Maximilian-University, and the University of Nottingham
approved the project. Cartilage explants were sliced and
digested primarily with 1% pronase for 2 h at 37◦C and
subsequently with 0.2% collagenase for 4 h at 37◦C. Isolated
chondrocytes were maintained in culture medium at a
density of 0.1 × 106 cells/mL in Petri dishes in monolayer
culture and on glass plates for a period of 24 h at 37◦C with
5% CO2.
2.5. Experimental Design. Serum-starved chondrocytes (pas-
sage two, cultivated in 3% FCS) were treated with the
botanical extracts (10 μg/mL) alone for 24 h (pretreatment)
and then cotreated with a combination of botanical extracts
(10 μg/mL) and IL-1β (10 ng/mL) for a further 48 h in
monolayer cultures. Chondrocytes treated with the botanical
extracts alone over the entire period served as treatments
and those treated with IL-1β were used as “inﬂammatory”
controls. In addition, untreated chondrocytes (i.e., cells only
exposed to serum-starved medium) served as untreated
controls. For investigation of NF-κB translocation and IκBα
phosphorylation, chondrocytes were treated either with IL-
1β (10 ng/mL) or cotreated with a combination of botanical
extracts (10 μg/mL) and IL-1β (10 ng/mL) for 0, 15, 30, and
60 min and nuclear/cytoplasmic extracts were prepared.
2.6. MTT Assay. Chondrocytes were seeded in 96-well plates
with 5000 cells/well and incubated overnight in culture
medium containing 10% FCS. Positive control cells were
left untreated or were treated with the compounds alone.
Negative controls were cells treated with IL-1β alone. Addi-
tionally, chondrocytes were incubated only with the same
quantity of DMSO in serum starved medium as in working
solutions (without the botanical extracts). For every control
and experimental treatment, three wells were used. For
measurements after 0, 24, 48, and 72 h, the medium (with or
without botanical extracts) was replaced with serum-starved
medium and MTT (10 μL) was added. After incubation for
4 h at 37◦C MTT solubilization solution was added and
cells were incubated at 37◦C until MTT formazan crystals
were completely dissolved. Absorbance was measured at a
wavelength of 550 nm with a spectrophotometer.
2.7. Immunoﬂuorescence Microscopy. Cells were cultivated
on glass plates and incubated for 24 h. The cells were then
washed three times and preincubated for 1 h with serum-
starved medium before stimulation with 10 ng/mL IL-1β
or 10 μg/mL botanical extracts alone or cotreated with
10 μg/mL botanical extracts and 10 ng/mL IL-1β for 30 min
in serum-starved (3% FCS) medium. Cells on the glass
plates were washed three-times in Hanks solution before
methanol ﬁxation for 10 min at ambient temperature (AT),
and rinsing with phosphate-buﬀered saline (PBS). Cell and
nuclear membranes of chondrocytes were permeabilized
by treatment with 0.1% Triton X-100 for 1 min on ice.
Cells were washed with bovine serum albumin (BSA) for
10 min at AT, rinsed with PBS, and incubated with primary
antibodies (p65, phospho-p65, 1 : 30 in PBS). They were
gently washed several times with PBS before incubation
with secondary antibody (goat-anti-rabbit immunoglobulin
conjugated with FITC, diluted 1 : 50 in PBS). Glass plates
were ﬁnally washed three-times with PBS, covered with ﬂuo-
romount mountant, and examined under a light microscope
(Axiophot 100, Zeiss, Germany).
2.8. Isolation of Nuclear and Cytoplasmic Chondrocyte Ex-
tracts. Chondrocytes were trypsinized and washed twice in
ice-cold PBS (1 mL). The supernatant was removed and cell
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pellets were resuspended in hypotonic lysis buﬀer (400 μL)
containing protease inhibitors. After incubation on ice
for 15 min, 10% NP-40 (12.5 μL) was added and the cell
suspension was vigorously mixed for 15 sec. The extracts
were centrifuged for 1.5 min. The supernatants (cytoplasmic
extracts) were frozen at −70◦C. Ice-cold nuclear extraction
buﬀer (25 μL) was added to the pellets and incubated for
30 min with intermittent mixing. Extracts were centrifuged
and the supernatant (nuclear extracts) transferred to pre-
chilled tubes for storage at −70◦C.
2.9. High-Density Cultures. The high density mass culture
was performed on a steel grid bridge as previously described
[5]. Brieﬂy, a cellulose ﬁlter was placed on the bridge onto
which a cell suspension (8 μL), containing approximately
1 million cells, was placed. Culture medium was in contact
with the ﬁlter and the cells were maintained at the ﬁlter-
medium interface through diﬀusion. After one day in cul-
ture, cells formed a three-dimensional pellet on the ﬁlter.
Culture medium was changed every three days.
2.10. Transmission Electron Microscopy (TEM). Cells were
ﬁxed for 1 h with Karnovsky’s ﬁxative (paraformaldehyde-
glutaraldehyde) followed by postﬁxation in 1% OsO4 solu-
tion (0.1 M phosphate buﬀer), as previously described [32].
Monolayer cell pellets were rinsed and dehydrated in an
ascending alcohol series before being embedded in Epon
and cut on a Reichert-Jung Ultracut E (Darmstadt, Ger-
many). Ultrathin sections were contrasted with 2% uranyl
acetate/lead citrate. A transmission electron microscope
(TEM 10, Zeiss, Jena, Germany) was used to examine the
cultures.
2.11. Western Blot Analysis. Chondrocyte monolayers were
washed three times with Hank’s balanced salt solution
(HBSS) and whole cell proteins were extracted by incubation
with lysis buﬀer (50 mM Tris/HCl, pH 7.2, 150 mM NaCl,
l% (v/v) Triton X-100, 1 mM sodium orthovanadate, 50 mM
sodium pyrophosphate, 100 mM sodium ﬂuoride, 0.01%
(v/v) aprotinin, 4 μg/mL pepstatin A, 10 μg/mL leupeptin,
1 mM PMSF) on ice for 30 min, and cell debris was removed
by centrifugation. Supernatants were stored at −70◦C. Total
protein concentration of whole cell, nuclear and cytoplasmic
extracts was determined according to the bicinchoninic acid
system (Uptima, Interchim, Montlucon, France) using BSA
as a standard. After adjusting the equal amounts (50 μg of
protein per lane) of total protein, proteins were separated
by SDS-PAGE (5, 7.5% gels) under reducing conditions.
The separated proteins were transferred onto nitrocellulose
membranes. Membranes were preincubated in blocking
buﬀer (5% (w/v) skimmed milk powder in PBS/0.1%
Tween-20) for 30 min and incubated with primary antibod-
ies (1 h, AT). Membranes were washed three times with
blocking buﬀer and incubated with alkaline phosphatase
conjugated secondary antibodies for 30 min. They were
ﬁnally washed three times in 0.1 M Tris pH 9.5 containing
0.05 M MgCl2 and 0.1 M NaCl. Nitro blue tetrazolium
and 5-bromo-4-chloro-3-indoylphosphate (p-toluidine salt;
Pierce, Rockford, IL, USA) were used as substrates to reveal
alkaline phosphatase-conjugated speciﬁc antigen-antibody
complexes.
2.12. Statistical Analysis. The results are expressed as the
means ± SD of a representative experiment performed in
triplicate. The means were compared using student’s t-test
assuming equal variances and P < 0.05 was considered
statistically signiﬁcant.
3. Results
This in vitro study was undertaken to investigate the anti-
inﬂammatory eﬀect of three botanical extracts on the sig-
naling pathway leading to the activation of the transcription
factor NF-κB and a selection of its target gene products,
namely, proteins important to chondrocyte function. Chon-
drocytes treated with botanical extracts (10 μg/mL) showed
no signs of cytotoxicity at the light and electron microscopic
(ultrastructural) levels. IL-1β was used to examine the eﬀect
of botanical extracts on the NF-κB activation pathway,
because the pathway activated by this cytokine is relatively
well understood.
3.1. Botanical Extracts Suppress IL-1β-Induced Chondrocyte
Cytotoxicity. To test IL-1β-inhibited chondrocyte prolifer-
ation an MTT assay was performed to study the eﬀects
of botanical extracts on the viability and proliferation of
chondrocytes treated with or without IL-1β. The MTT
assay is based on the ability of living cells to reduce
the MTT salt, whereas dead cells or those with impaired
mitochondrial activity are unable to do so. Chondrocytes
were cultured in a 96-well plate and treated with IL-1β,
botanical extracts, and botanical extracts then treated with
IL-1β for the indicated times. The viability and proliferation
of the chondrocytes cultivated only in the presence of IL-1β
was signiﬁcantly lower compared to those of chondrocytes
treated with botanical extracts, botanical extracts and IL-1β,
or left untreated (Figure 1). The results showed a positive
eﬀect of three botanical extracts with regard to cell viability
and proliferation on inhibiting IL-1β-induced cytotoxicity
on chondrocytes.
3.2. Botanical Extracts Block IL-1β-Induced Cellular/Ultra-
structural Changes and Apoptosis in Chondrocytes. Con-
trol monolayer chondrocytes after 24 (not shown), 48
(Figure 2(a)), and 72 h (not shown) showed a typical ﬂat-
tened shape with small cytoplasmic processes, a large, mostly
euchromatic nucleus with nucleoli and a well-structured
cytoplasm. IL-1β-treatment of chondrocyte monolayer cul-
tures for 24 (data not shown) and 48 h (Figure 2(b)) lead to
degenerative changes such as multiple vacuoles, swelling of
rough ER, clustering of swollen mitochondria, and degener-
ation of other cell organelles. After longer incubation periods
(72 h) (data not shown) more severe features of cellular
degeneration were seen in response to IL-1β treatment. These
included areas of condensed heterochromatin in the cell
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Figure 1: Eﬀect of botanical extracts and IL-1β on the proliferation
of chondrocytes in vitro. Serum-starved chondrocytes were exposed
to IL-1β (10 ng/mL) for 48 h, botanical extracts (10 μg/mL) for
72 h, cotreated ﬁrst with botanical extracts (10 μg/mL each) for
24 h, and then with IL-1β (10 ng/mL) for 48 h, treated with DMSO
(as control) for 72 h or left untreated for 72 h. Cell viability was
examined by MTT assay. The MTT assay is a spectrophotometric
measurement of the cell viability as a function of the mitochondrial
activity. This assay was performed in triplicate and the results
are provided as mean values with standard deviations from three
independent experiments. Treatments: Untreated control; IL-1β;
RC (Rosa canina); SA (Salix alba); UD (Urtica dioica).
nuclei and multiple cytoplasmic vacuoles. The ﬂattened
monolayer chondrocytes became increasingly rounded and
apoptotic (Figure 2(b)). Chondrocytes pretreated with any of
the botanical extracts (10 μg/mL) (24 h) and then cotreated
with IL-1β and the same botanical extracts (10 μg/mL)
for 48 h showed less severe cellular degeneration on the
ultrastructural level (Figures 2(c)–2(e)). The chondrocytes
remained a ﬂattened shape with numerous microvilli-like
cytoplasmic processes. Chondrocytes treated with botan-
ical extracts alone (each at 10 μg/mL) showed no signs
of cytotoxic eﬀects on the viability of cells at the light
microscopic and ultrastructural levels (Figures 2(f)–2(h)).
Taken together, these results indicate that all three botanical
extracts have antiapoptotic eﬀects and counteract IL-1β-
induced apoptosis in chondrocytes.
3.3. Botanical Extracts Inhibit IL-1β-Induced Downregulation
of Extracellular Matrix and Signaling Proteins in Chondro-
cytes. Serum-starved chondrocytes were treated with IL-
1β (10 ng/mL) alone or were preincubated with three
diﬀerent botanical extracts (10 μg/mL each) for 24 h and
then cotreated with IL-1β (10 ng/mL) for 24, 48, and 72 h.
As shown in Figure 3, chondrocytes stimulated with IL-
1β alone showed downregulation of synthesis of collagen
type II (Figure 3(I)), cartilage-speciﬁc proteoglycan (CSPG)
(Figure 3(II)), and β1-integrin (Figure 3(III)). In contrast
to chondrocytes stimulated with IL-1β alone, pretreatment
with all botanical extracts resulted in a signiﬁcant up-
regulation of synthesis of collagen type II (Figure 3(I)),
CSPG, (Figure 3(II)) and β1-integrin (Figure 3(III)). In
untreated and in positive control cultures, expression of
collagen type II, CSPG, and β1-integrin were equally
strong in chondrocytes (Figures 3(I)–3(III)). Synthesis of
the housekeeping protein β-actin remained unaﬀected in
chondrocytes exposed to botanicals (Figure 3(IV)).
3.4. Botanical Extracts Inhibit IL-1β-Induced Upregulation
of NF-κB-Dependent ProInﬂammatory Enzymes and Matrix
Degrading Gene Products in Chondrocytes. IL-1β stimulation
activates COX-2 and MMPs expression in chondrocytes [33].
To investigate whether the three botanical extracts were
able to inhibit IL-1β-induced expression of these proteins,
the following experiment was performed. Serum-starved
chondrocytes were exposed to IL-1β (10 ng/mL) alone or
were preincubated with three diﬀerent botanical extracts
(10 μg/mL each) for 24 hours and then co-treated with IL-1β
(10 ng/mL) for 24, 48 and 72 h. The whole cell extracts were
prepared and analyzed by western blotting for the presence
of COX-2, MMP-9 and MMP-13 (Figures 4(I)–4(III)). As
shown in Figure 4, chondrocytes showed up-regulation of
synthesis of COX-2 (Figure 4(I)), MMP-9 (Figure 4(II)) and
MMP-13 (Figure 4(III)) in response to IL-1β (10 ng/mL). In
contrast to chondrocytes stimulated with IL-1β alone, pre-
treatment with all botanical extracts and co-treatment with
IL-1β led to a decrease in COX-2, MMP-9 and MMP-13
expression (Figures 4(I)–4(III)). In untreated and positive
control cultures, expression of COX-2, MMP-9, and MMP-
13 was not detectable in chondrocytes (Figures 4(I)–4(III)).
Synthesis of the housekeeping protein β-actin remained
unaﬀected (Figure 4(IV)).
3.5. Botanical Extracts Inhibit the IL-1β-Induced Downreg-
ulation of Adaptor Protein Shc, Signaling Protein P-ERK1/2,
and Cartilage-Speciﬁc Transcription Factor SOX-9 Expression
in Chondrocytes. The MAPKinase pathway plays an impor-
tant role in chondrocyte diﬀerentiation and stimulates the
chondrogenic factor SOX-9 in chondrocytes [7, 8]. SOX-
9 is a transcription factor that controls the expression of
chondrocyte-speciﬁc ECM protein genes and plays a pivotal
role in chondrocyte diﬀerentiation, thus it was selected for
this study. Additionally, the MAPKinase signaling pathway,
the adaptor protein Shc and the extracellular regulated
kinase (Erk1/2) were evaluated. To test the hypothesis that
botanical extracts are able to stimulate SOX-9 production in
chondrocytes, monolayer cultures were either left untreated
or treated with IL-1β or botanical extracts alone or were
pretreated with botanical extracts (10 μg/mL) for 24 h and
then stimulated with IL-1β for 24 h. The cell lysates were
analyzed by immunoblotting. In untreated and in positive
control cultures, expression of Shc, ERK1/2, and SOX-9 were
equally strong in chondrocytes (Figures 5(I)–5(III)). The
results demonstrated that treatment with the three botanical
extracts inhibited the IL-1β-induced decrease in Shc, ERK1/2
and SOX-9 expression (Figures 5(I)–5(III)). Data shown are
representative of three independent experiments. Synthesis
of the housekeeping protein β-actin remained unaﬀected
(Figure 5(IV)).
3.6. Botanical Extracts Inhibit IL-1β-Induced NF-κB Acti-
vation in Chondrocytes. To examine if botanical extracts
block the IL-1β-induced activation of NF-κB, nuclear protein
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Figure 2: Eﬀect of botanical extracts on IL-1β-induced cell degradation and apoptosis. Serum-starved chondrocytes were either left
untreated, (a) exposed to IL-1β (10 ng/mL) alone (b), or to botanical extracts alone (f–h) for 1, 12, 24, 48, and 72 h or pretreated for
24 h with botanical extracts (10 μg/mL) before being cotreated with IL-1β (10 ng/mL) and botanical extracts (10 μg/ml) (c–e) and evaluated
with TEM. Chondrocytes treated with IL-1β (10 ng/mL) exhibited characteristic features of degeneration: annular chromatin condensation
at the nuclear envelope of chondrocytes, swelling of mitochondria, and rough ER in a time-dependent manner (b). Chondrocytes that were
pretreated with botanical extracts and then cotreated with IL-1β and botanical extracts (panels c–e) showed less severe cell degeneration at
the ultrastructural level. In control cultures (a) and treated with botanical extracts alone (panels f–h) showed no ultrastructural changes.
A–M: ×5000; Bar = 1 μm. Treatments: Rosa canina + IL-1β, panel (c); Salix alba + IL-1β, panel (d); Urtica dioica + IL-1β, panel (e); Rosa
canina without IL-1β, panel (f); Salix alba without IL-1β, panel (g); Urtica dioica without IL-1β, panel (h).
extracts from serum-starved chondrocytes were probed
for the phosphorylated form of p65 NF-κB-subunit after
pretreatment with botanical extracts (10 μg/mL each) for
4 hours followed by cotreatment with 10 ng/mL IL-1β
and botanical extracts for 1 h. Some chondrocyte cultures
remained either untreated or were treated with 10 μg/mL
botanical extracts (each alone) or with 10 ng/mL IL-1β alone
for 1 h (Figure 6(I)). Results indicate that botanical extracts
inhibited IL-1β-induced NF-κB activation (Figure 6(I)).
The synthesis of the PARP protein remained unaﬀected
(Figure 6(II)).
3.7. Botanical Extracts Inhibit IL-1β-Stimulated Nuclear-
Translocation of NF-κB in Chondrocytes. Immunoﬂuores-
cence microscopy was employed to reveal translocation of
phosphorylated NF-κB from the chondrocyte cytoplasm to
the nucleus in response to IL-1β. Chondrocytes remained
either unstimulated (Figure 7(a)) or were treated with
10 μg/mL botanical extracts (each alone) or with 10 ng/mL
IL-1β alone for 10 min (Figure 7(b)) or were cotreated
with 10 μg/mL botanical extracts (each alone) 10 min and
then 10 ng/mL IL-1β for 1h (Figures 7(c)–7(e)) before
indirect immunolabeling with anti-NF-κB antibody. Control
chondrocytes and chondrocytes treated with the botanical
extracts alone (not shown) showed only cytoplasmic labeling
of NF-κB (Figure 7(a)). IL-1β-stimulated cells revealed clear
and intensive cytoplasmic and nuclear staining for NF-κB
(Figure 7(b)). Cotreatment of chondrocytes with botanicals
and IL-1β resulted in inhibition of nuclear transition of
activated phosphor-p65 and decreased cytoplasmic staining
for this protein and showed a decrease in activation of
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Figure 3: Eﬀects of botanical extracts on IL-1β-induced downregulation of extracellular matrix and signaling proteins in chondrocytes.
Serum-starved chondrocytes (0.1 × 106 cells/mL) were cultured for 24 h and then treated with 10 ng/mL IL-1β for 48 h, botanical extracts
(each 10 μg/ml) for 72 h, or pretreated with botanical extracts (10 μg/mL each) for 24 h and then cotreated with 10 ng/mL IL-1β for 48 h or
left untreated and evaluated after 72 h. Western blot analysis revealed down-regulation of collagen type II (I), CSPG (II) and β1-integrin
(III) in chondrocytes by IL-1β. Co-treatment of chondrocytes preincubated with botanical extracts and IL-1β suppressed the IL-1β-induced
inhibition of collagen type II, CSPG and β1-integrin (I, II, III). In untreated and in botanical extracts alone treated control cultures,
expression of collagen type II, CSPG and β1-integrin were equally strong in chondrocytes (I–III). Expression of β-actin was not aﬀected by
IL-1β and/or botanical extracts (IV). Data shown are representative of three independent experiments. Treatments: C (untreated control);
IL-1β; RC (Rosa canina); SA (Salix alba); UD (Urtica dioica).
NF-κB (Figures 7(c)–7(e)). These immunomorphological
ﬁndings were consistent with the NF-κB inhibition observed
by western blotting.
3.8. Botanical Extracts Inhibit IL-1β-Induced IκBα Degrada-
tion in Chondrocytes. In this study, botanical extracts inhib-
ited IL-1β-induced activation of NF-κB and its translocation
to the chondrocyte nucleus. An important prerequisite for
the activation of NF-κB is the phosphorylation and degra-
dation of IκBα, the natural blocker of NF-κB [34]. To
examine whether inhibition of IL-1β-induced NF-κB acti-
vation occurs through inhibition of IκBα degradation, some
chondrocyte cultures were treated with IL-1β (10 ng/mL) for
the indicated times (Figures 8(I)–8(III)) and other chondro-
cyte cultures were ﬁrst treated with three botanical extracts
(10 μg/mL each) for 4 h followed by co-treatment with IL-1β
(10 ng/mL) for the indicated time periods. IL-1β could not
induce IκBα degradation in chondrocytes when co-treated
with botanical extracts (Figures 8(I)–8(III)). Considering,
IL-1β-induced IκBα degradation in untreated cultures is an
indicator of NF-κB activation, the results suggest that the
botanical extracts block IL-1β-induced IκBα degradation.
3.9. Botanical Extracts Inhibit IL-1β-Dependent IκBα Phos-
phorylation in Chondrocytes. To determine if the botanical
extracts are able to inhibit the IL-1β-induced phosphoryla-
tion of IκBα, serum-starved chondrocytes were treated with
IL-1β for 1h and examined by western blot analysis using an
antibody that recognizes the phosphorylated form of IκBα. It
is known that phosphorylation of IκBα leads to its degrada-
tion [16], and that the phosphorylation and degradation of
IκBα are inhibited by a speciﬁc proteosome inhibitor N-Ac-
Leu-Leu-norleucinal (ALLN) [35]. As shown in Figures 9(I)–
9(III), IL-1β was still able to phosphorylate some IκBα in cells
pretreated with the inhibitor and IκBα phosphorylation was
signiﬁcantly higher compared to control cells. Interestingly,
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Figure 4: Eﬀects of botanical extracts on IL-1β-induced upregulation of proinﬂammatory enzymes in chondrocytes. Serum-starved
chondrocytes (0.1× 106 cells/mL) were cultured for 24 h and then treated with 10 ng/mL IL-1β for 48 h, botanical extracts (each 10 μg/mL)
for 72 h, or pretreated with botanical extracts (10 μg/mL each) for 24 h and then cotreated with 10 ng/mL IL-1β for 48 h or left untreated
and evaluated after 72 h. IL-1β-stimulation leads to an increase in synthesis of COX-2, MMP-9, and MMP-13 (I, II, III). However, COX-
2, MMP-9, and MMP-13 upregulation was blocked in chondrocytes pre-incubated with botanical extracts (10 μg/mL each) for 24 h and
then co-treated with IL-1β (10 ng/mL) for 48 h (I, II, III). In untreated and in botanical extracts alone treated control cultures, expression
of COX-2-, MMP-9 and MMP-13 were not seen in chondrocytes (I–III). Expression of the housekeeping gene β-actin was not aﬀected
by treatment with IL-1β and/or botanical extracts (IV). Data shown are representative of three independent experiments. Treatments: C
(untreated control); IL-1β; RC (Rosa canina); SA (Salix alba); UD (Urtica dioica).
all botanical extracts were able to inhibit the phosphorylation
of IκBα induced by IL-1β in the presence or absence of the
inhibitor.
3.10. Botanical Extracts Inhibit IL-1β-Induced Eﬀects in a 3-
Dimensional (High-Density) Culture Model of Chondrocytes.
To test whether chondrocytes from monolayer cultures with
or without IL-1β and/or botanicals were able to produce
cartilage-speciﬁc ECM and cartilage, high-density cultures
were prepared from chondrocytes in monolayer culture.
These consisted of untreated control cells and cells treated
with botanical extracts (10 μg/mL) or IL-1β (10 ng/mL)
alone for 24 h before being treated with IL-1β (10 ng/mL)
and cultivated for 7 days under identical conditions.
As shown in Figure 10, control cultures of chondrocytes
formed blastema-like nodules and made tight contacts. They
exhibited round to oval shapes, large euchromatic nuclei,
free cytoplasmic ribosomes, mitochondria and endoplasmic
reticulum (ER), as well as vacuoles. The cells appeared
as viable chondrocytes exhibiting characteristic morpho-
logical features and formed a regular ﬁbrillar extracellular
matrix (Figure 10(a)). In contrast, chondrocytes under-
went apoptosis when treated with IL-1β (10 ng/mL) for 7
days (Figure 10(b)). Chondrocytes co-treated with botanical
extracts and IL-1β (each 10 μg/mL) showed well-developed
cartilage nodules (Figures 10(c)–10(e)). Pre-treatment with
botanical extracts (each 10 μg/mL) alone resulted in well-
developed cartilage nodules with viable cells and organized
organelles; the cells formed a dense and regular ECM
(Figures 10(f)–10(h)).
4. Discussion
The goal of this study was to characterize the eﬀect and mode
of action of three botanical extracts derived from plants with
previously reported anti-inﬂammatory activity on NF-κB
expression in primary canine chondrocytes in vitro. Under
the experimental conditions, (1) botanical extracts inhibited
the IL-1β-mediated suppression of key extracellular matrix
and signaling proteins in chondrocytes; (2) botanical extracts
antagonized the IL-1β-dependent upregulation of MMP-9,
MMP-13, and COX-2; (3) IL-1β caused phosphorylation and
nuclear translocation of the p65 NF-κB subunit; (4) IL-1β
caused phosphorylation and subsequent degradation of the
inhibitory subunit of NF-κB: IκBα; (5) IL-1β-induced NF-κB
activation and IκBα degradation was inhibited by botanicals;
(6) ﬁnally, in contrast to IL-1β-treated cells, the cells treated
with botanical extracts rediﬀerentiated into chondrocytes
after transfer to high-density culture and produced a
cartilage-speciﬁc matrix, that is, collagen type II, even when
cotreated with IL-1β. Therefore, the results obtained strongly
suggest that the botanical extracts inhibit IL-1β-induced up-
regulation of MMP-9, MMP-13, and COX-2 by preventing,
at least in part, IκBα degradation and NF-κB activation. The
schematic in Figure 11 summarizes the possible mode of
action of the botanical extracts.
Systematic reviews of clinical studies show little evidence
to support botanical remedies as eﬃcacious the treatment
for OA [36]. However, the three plants from which extracts
have been analyzed in this study have been used in traditional
medicines for many centuries and all had claims related
to treatment for OA. Whilst patients continue to seek
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Figure 5: Eﬀect of botanical extracts on signaling proteins and cartilage-speciﬁc transcription factor SOX-9 in chondrocytes. Serum-starved
chondrocytes (0.1× 106 cells/mL) were cultured for 24 h and then treated with 10 ng/mL IL-1β for 48 h, botanical extracts (each 10 μg/mL)
for 72 h, or pretreated with botanical extracts (10 μg/mL each) for 24 h and then cotreated with 10 ng/mL IL-1β for 48 h or left untreated
and evaluated after 72 h. Results of western blot analysis revealed down-regulation of Shc (I), ERK1/2 (II), and SOX-9 (III) in chondrocytes
with IL-1β. Cotreatment of chondrocytes preincubated with botanical extracts and IL-1β relieved the IL-1β-induced inhibition of Shc (I),
ERK1/2 (II), and SOX-9 (III). In untreated and in positive control cultures, expression of Shc, ERK1/2, and SOX-9 were equally strong in
chondrocytes (I–III). Expression of β-actin was not aﬀected by IL-1β and/or botanical extracts (IV). Data shown are representative of three
independent experiments. Treatments: C (untreated control); IL-1β; RC (Rosa canina); SA (Salix alba); UD (Urtica dioica).
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Figure 6: Botanical extracts block the IL-1β-induced phosphorylation and nuclear translocation of p65 in chondrocytes. Western blot
analysis of IL-1β-treated nuclear extracts. Serum-starved chondrocytes (0.1×106 cells/mL) were pretreated with botanical extracts (10 μg/ML
each) for 4 hours followed by cotreatment with 10 ng/mL IL-1β and botanical extracts for 1 h. Some chondrocyte cultures remained either
untreated or were treated with 10 μg/mL botanical extracts (each alone) or with 10 ng/mL IL-1β alone for 1 h. Nuclear extracts were
probed for phospho p65, (I) by western blot analysis using antibodies to p65, phospho-speciﬁc p65, and PARP (II, control). Treatment
of chondrocytes with IL-1β (10 ng/mL) revealed a clear increase in expression of phospho-p65 in the nuclear extracts (I). Co-treatment
of chondrocytes with botanical extracts (all three) completely abolished the IL-1β-dependent activation of phospho p65 in the nucleus (I).
Synthesis of PARP remained unaﬀected in nuclear extracts (II). Data shown are representative of three independent experiments. Treatments:
C (untreated control); IL-1β; RC (Rosa canina); SA (Salix alba); UD (Urtica dioica).
natural remedies to help treat themselves or their companion
animals, it is important to provide insights into whether, and
if so how, such botanicals may work. As such, in vitro models
provide an objective benchmark to indicate potential modes
of action if translated in vivo.
The three botanical extracts in this study are derived
from diﬀerent parts of the plant and previous publications
have claimed diﬀerent active components. The data provided
in this study may be used to suggest that there are actives
in all three botanicals that can inhibit the IL-1β-induced
inﬂammatory process upstream of the IκBα phosphoryla-
tion step. Whilst the exact mechanism of action remains
unknown, the data may also be used to indicate that IL-
1β-suppressing activities are common to a number of plant
species and tissues. With a growing number of publications
claiming speciﬁc actives, it may be an appropriate time to
consider commonalities of botanical extracts rather than
focus attention on “unique” attributes of a multitude of
speciﬁc plants, which may lead to confusion and skepticism
toward the area of phytotherapy.
All three botanical extracts had a positive eﬀect on
chondrocyte viability, diﬀerentiation and function as well as
having inhibitory eﬀects on IL-1β-induced suppression of
proliferation and viability. Furthermore, the three botanicals
enhanced mitochondrial activity in chondrocytes, as mea-
sured using the MTT assay. Reports have observed botanicals
that interfere with the assay through antioxidant (e.g., thiols
and ﬂavonoids) reduction of MTT [37], and we have also
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Figure 7: Botanical extracts inhibit IL-1β-induced nuclear translocation of NF-κB in chondrocytes. Chondrocyte cultures either served as
controls (a) or were treated with IL-1β alone for 10 min (b) or cotreated with botanical extracts for 10 min and then cotreated with IL-1β
for 1 h (c–e) before immunolabeling with NF-κB antibodies and FITC-coupled secondary antibodies. In control cells anti-NF-κB labeling
was restricted to the cytoplasm (a). Cells treated with IL-1β alone revealed nuclear translocation of NF-κB (b) that was partly inhibited by
cotreatment with botanical extracts (c–e). (a–e): ×160. Data shown are representative of three independent experiments.
observed signiﬁcant negative and insigniﬁcant responses
with other botanicals (data not shown). Whilst the exact
reason for the enhanced mitochondrial activity was not
investigated, it was considered an indicator of enhanced me-
tabolism and, as such, was considered a potentially positive
attribute.
Cell-matrix interactions in cartilage are essential for
the proliferation, diﬀerentiation and survival of cells and
this interaction is mediated by speciﬁc surface receptors,
for example, integrins [6, 7, 38]. β1-integrins are able to
organize cell surface mechanoreceptor complexes [39] and
function as signal transduction molecules [40] stimulating
MAPkinase pathways [7, 8]. Several studies have already
shown that reduced cell-matrix interactions lead to inhibi-
tion of Erk1/2 signaling and stimulate the apoptotic pathway
in chondrocytes [8]. In this in vitro model system, IL-1β
induced downregulation of collagen type II, CSPG, and
integrin expression in chondrocytes. These ﬁndings are in
agreement with previous in vitro studies [18]. Treatment
with three botanicals prevented the IL-1β-induced inhibition
of collagen type II, CSPG, and integrin expression in IL-1β-
stimulated chondrocytes.
In this study, IL-1β induced upregulation of MMP-9,
MMP-13, and COX-2. Cell-matrix interaction requires a
permanent remodeling of extracellular matrix proteins exe-
cuted by MMPs, a group of zinc-dependent endopeptidases
that cleave ECM molecules [41] and high levels of MMPs
(MMP-1, MMP-3, MMP-9, and MMP-13) are found in the
synovium and serum of OA and RA patients [42, 43]. COX-2
is an important mediator of pain and inﬂammation in OA
joints [44] causing PGE2 and thromboxane production [45].
PGE2 induces many other pathological catabolic eﬀects in
cartilage such as decreased proliferation of chondrocytes and
inhibition of ECM synthesis [45]. We suggest that the down-
regulation of MMPs and COX-2 by botanicals is regulated, at
least in part, via NF-κB inhibition, because the expression of
these enzymes is regulated by NF-κB [33, 46–48].
Cytokine-induced MMP and COX-2 upregulation is
regulated by activation of the ubiquitous transcription factor
NF-κB [49]. This transcription factor plays an important
role during the pathogenesis of OA, by mediating the
expression of catabolic and inﬂammation-related genes.
Interestingly, inhibitors of NF-κB have anti-inﬂammatory
and antidegradative eﬀects in animal models of OA [50].
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Figure 9: Eﬀect of botanical extracts on the phosphorylation of IκBα by IL-1β in chondrocytes. Western blot analysis with IL-1β-treated
cytoplasmic extracts. Serum-starved chondrocytes (0.1×106 cells/mL) were pretreated with ALLN (100 μg/mL) for 30 min and cotreated with
botanical extracts (each 10 μg/mL) for 4 h and stimulated with IL-1β (10 ng/mL) for the ﬁnal 1 h. The cytoplasmic extracts were prepared,
fractionated on SDS-PAGE, and electroblotted onto nitrocellulose membranes. Western blot analysis was performed using anti-IκBα and
p-IκBα antibodies. Treatment of chondrocytes with IL-1β (10 ng/mL) revealed an increase in the phosphorylated IκBα-form in cytoplasmic
extracts. In the presence of the inhibitor phosphorylation of IκBα was signiﬁcantly increased (I–III). Phosphorylation of IκBα was inhibited
in chondrocytes cotreated with botanical extracts in the presence or absence of the inhibitor (I–III). Data shown are representative of three
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Figure 10: Cultivation of chondrocytes in a 3-dimensional culture system (High-density cultures) in vitro in the presence of botanical extracts.
Chondrocytes were treated with botanical extracts (10 μg/mL) or IL-1β (10 ng/mL) alone for 24 h before being treated with IL-1β (10 ng/mL)
for 7 days in high-density cultures. Control cultures of chondrocytes showed well-developed cartilage nodules (a). Treatment with IL-1β
resulted in cell destruction after 7 days (b). After the cotreatment of high-density cultures with botanical extracts and IL-1β (panels c–e)
or in the absence of IL-1β (panels f–h) the chondrocytes exhibited well-developed cartilage nodules. ×4000; bars: 1 μm. Treatments: Rosa
canina + IL-1β, panel (c); Salix alba + IL-1β, panel (d); Urtica dioica + IL-1β, panel (e); Rosa canina without IL-1β, panel (f); Salix alba
without IL-1β, panel (g); Urtica dioica without IL-1β, panel (h).
In the present study, increased phosphorylation of p65 in
response to IL-1β was demonstrated. This phosphorylation
event, in turn, leads to its degradation and subsequent
release of activated NF-κB. The results also showed that
IκBα was completely abolished in the cytoplasmic extracts
in chondrocyte cultures treated with IL-1β alone, indicating
that this cytokine induced its degradation. This indicates NF-
κB activation. Treatment of the chondrocyte cultures with
the botanical extracts resulted in high concentrations of IκBα
in the cytoplasm and decreased levels of phosphorylated
p65 in nuclear extracts. These results strongly suggest that
the botanical extracts inhibit IL-1β-induced downregulation
of cartilage speciﬁc ECM compounds, MAPK-signaling
proteins, cartilage-speciﬁc transcription factors and upregu-
lation of proinﬂammatory and degrading enzymes through
NF-κB activation by preventing, at least in part, IκBα
phosphorylation and degradation.
The cartilage-speciﬁc transcription factor SOX-9 plays
an important role in the expression of cartilage-speciﬁc
extracellular matrix genes [51]. In this study, a reduction
in collagen type II and SOX-9 expression in chondrocytes
after treatment with IL-1β was observed, in agreement with
another study [52]. Other investigators have shown that
cytokines partially reduce SOX-9 protein levels through a
NF-κB-dependent, posttranscriptional mechanism in mouse
chondrocytes [18]. However, by treating cells with the
botanical extracts, inhibition of the IL-1β-induced NF-κB-
dependent downregulation of collagen type II and SOX-9
expression was observed. The results of this study suggest
that the botanical extracts markedly suppressed cytokine-
induced activation and upregulation of proinﬂammatory
enzymes such as MMPs and COX-2, transcription factor
NF-κB and downregulation of cartilage-speciﬁc matrix com-
ponents and important signaling proteins in chondrocytes.
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Figure 11: Inhibitory eﬀects of botanical extracts on IL-1β-induced NF-κB activation in chondrocytes in vitro. IL-1β stimulates the IL-
1β receptor, initiating an intracellular signal transduction cascade, which activates the cytoplasmic IκBα kinases (Iκκ)-α, Iκκ-β, and Iκκ-γ.
These kinases phosphorylate inactive IκBα. Phosphorylated IκBα is then ubiquitinated and degraded by the proteasome and active NF-
κB is released. NF-κB translocates to the nucleus, where it activates proinﬂammatory and proapoptotic gene production. In chondrocytes,
botanical extracts inhibit the NF-κB signal transduction pathway, ubiquitination of phosphorylated IκBα and block translocation of activated
NF-κB to the nucleus.
Whilst botanical extracts may exhibit multiple modes of
action, based on the IκBα phosphorylation data, it is prob-
able that inhibition of the IL-1β signaling pathway upstream
of IκBα phosphorylation is likely to be the major cause of the
anti-inﬂammatory activity observed in this study. Monolayer
cultures of chondrocytes appear to be a valid model for
investigating the mode of action of plant extracts with
potential anti-inﬂammatory properties. However, in vivo
chondrocytes exist within a three-dimensional extracellular
matrix. Therefore, studies were also performed using high-
density cultures, which indicated that the botanical extracts
do inhibit IL-1β-induced inﬂammation and apoptosis,
allowing the cells in high-density cultures to rediﬀerentiate
back into chondrocytes.
5. Conclusion
The three botanical extracts used in this study were derived
from diﬀerent parts of the plants used in traditional
medicine. Previous publications have claimed diﬀerent active
components and several constituents which have anti-
inﬂammatory eﬀects. In this study similar in vitro eﬀects
of these three diﬀerent botanical extracts are important
observations and can be used to support the view that they
may be potential chondroprotective agents. However, further
investigations are needed to characterize the biological enti-
ties present within the extracts, to elucidate their subcellular
targets in vitro and to determine whether they are capable of
any similar activity or synergism in vivo.
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